TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02187055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib with methotrexate
Description: Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib without methotrexate
Description: Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Study: NCT02187055

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab with methotrexate
Description: Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
Study: NCT03915457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry immersion Control Group
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
Study: NCT01172145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
Study: NCT02009462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefill dermal filler
Description: Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
Study: NCT04487691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nebulized Platelet Lysate
Description: Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (\~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sterile Saline
Description: Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
Study: NCT02615028

Intervention type: OTHER
Group type: OTHER
Intervention: Closed eyes double-leg stance
Description: Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
Study: NCT02284750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Study: NCT03545451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videogames
Description: Videogames
Study: NCT01783561

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
Study: NCT01852747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multilevel Spinal fusion with Actifuse ABX®
Description: Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
Study: NCT03266263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatic computer-led feedback
Description: automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instructor-led feedback
Description: feedback for CPR quality by instructors
Study: NCT01111461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
Study: NCT01352091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex+AI
Description: Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAM
Description: Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
Study: NCT01377779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxiplex/AP gel
Description: Intrauterine application of Intercoat following hysteroscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: No intrauterine application of Intercoat following hysteroscopy
Study: NCT04203147

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy (Control)
Description: Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home DM-BAT
Description: Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
Study: NCT01289691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Lung Ventilation
Description: Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Lung Ventilation
Description: Patients in this group will be ventilated with only oxygen during one lung ventilation.
Study: NCT01689311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergonovine
Description: Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha
Description: Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study: NCT03706794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Tool
Description: Tailored education provided via a smartphone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache Education
Description: Non-tailored education provided via a smartphone application.
Study: NCT03378492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Epidural
Description: Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural
Description: The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
Study: NCT01986491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
Study: NCT03915457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thigh cuffs intervention
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
Study: NCT04588272

Intervention type: DEVICE
Intervention: DualGuard
Description: DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.

Intervention type: DEVICE
Intervention: DualGuard
Description: DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.

Intervention type: DEVICE
Intervention: DualGuard
Description: DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
Study: NCT03870321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core training
Description: In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise.
Study: NCT03419468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Geriatric Assessment Measure (SGAM)
Description: Self Geriatric Assessment Measure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Geriatric Assessment Measure (SGAM)
Description: Self Geriatric Assessment Measure
Study: NCT03893708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal yoga
Description: The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy education
Description: Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
Study: NCT03734094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic barrier
Description: The use of a ceramic barrier to induce bone formation during GBR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium Mesh
Description: The use of a titanium mesh to induce bone formation during GBR
Study: NCT04267575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canady Helios Cold Plasma Scalpel
Description: Device used to distribute cold plasma energy at the resected tumor margins.
Study: NCT01049074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
Study: NCT02032667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-player condition
Description: Children in the multi-player condition will be able to play with and compete against other children in real time.
Study: NCT01986491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
Study: NCT01272986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALOA IgG-Elisa
Description: measurement of IgG Level in blood

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALOA IgG-Elisa
Description: measurement of IgG Level in blood
Study: NCT02615353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: 6-months of lifestyle education

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Control
Description: Medical visit and dietary counseling
Study: NCT00588224

Intervention type: OTHER
Intervention: 3D ultrasound
Description: measurement of stomach volume by 3D ultrasound
Study: NCT01272986

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ALOA IgG-Elisa
Description: measurement of IgG Level in blood

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALOA IgG-AtheroAbzyme
Description: measurement of IgG in blood

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALOA IgG-AtheroAbzyme
Description: measurement of IgG in blood
Study: NCT01449487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPC-5650
Description: Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for administration in the rectum Identical tp active solution but without active drug
Study: NCT00395382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70mg weekly orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly orally
Study: NCT03073447

Intervention type: OTHER
Group type: OTHER
Intervention: Specific blood sample of women under 50 years with acute MI
Description: The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
Study: NCT00902967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg, once a day dosing at night after meals
Study: NCT01272986

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ALOA IgG-AtheroAbzyme
Description: measurement of IgG in blood
Study: NCT00902967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets of similar shape size and color given once a day at night time after meals
Study: NCT00309179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820 plus cetuximab
Description: Escalating doses from 40 mg/m\^2 irinotecan plus E7820 in combination with cetuximab.
Study: NCT00652041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
Study: NCT01986491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Study: NCT01501422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Description: 50 microgram estrogen patch weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo patch for 8 weeks
Study: NCT02501135

Intervention type: PROCEDURE
Intervention: Femoral nerve block with ropivacaine or bupivacaine